Use of brodalumab for the treatment of psoriasis and psoriatic arthritis.
Psoriasis is a chronic immune-mediated disease that affects 2-3% of the population worldwide. Over the past two decades new data on the physiopathology of psoriasis have opened the door for novel therapeutic options. The IL-23-Th17 axis has been shown to play a key role in the inflammatory cascade central to this disease. IL-17 inhibitors are a new group of drugs that have shown excellent clinical effectiveness for the treatment of moderate-to-severe psoriasis in current clinical trials. Brodalumab is an antibody against IL-17 receptor subunit A (IL-17RA). This article reviews the available published data on brodalumab for the treatment of moderate-to-severe psoriasis and psoriatic arthritis.